HK1200440A1 - 種抑制劑的結晶形式 - Google Patents
種抑制劑的結晶形式Info
- Publication number
- HK1200440A1 HK1200440A1 HK15100810.1A HK15100810A HK1200440A1 HK 1200440 A1 HK1200440 A1 HK 1200440A1 HK 15100810 A HK15100810 A HK 15100810A HK 1200440 A1 HK1200440 A1 HK 1200440A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- inhibitor
- crystalline forms
- crystalline
- forms
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86874806P | 2006-12-06 | 2006-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1200440A1 true HK1200440A1 (zh) | 2015-08-07 |
Family
ID=39205161
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10104322.9A HK1138567A1 (zh) | 2006-12-06 | 2010-05-03 | '- '- '- -叔丁基苯基 草氨酰基 丙氨酰基 氨基- ', ', ', '-四氟苯氧基 -氧代戊酸的結晶形式 |
HK15100168.9A HK1199885A1 (zh) | 2006-12-06 | 2015-01-07 | '- '- '- -叔丁基苯基 草氨酰基 丙氨酰基 氨基- ', ', ', '-四氟苯氧基 -氧代戊酸的結晶形式 |
HK15100810.1A HK1200440A1 (zh) | 2006-12-06 | 2015-01-23 | 種抑制劑的結晶形式 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK10104322.9A HK1138567A1 (zh) | 2006-12-06 | 2010-05-03 | '- '- '- -叔丁基苯基 草氨酰基 丙氨酰基 氨基- ', ', ', '-四氟苯氧基 -氧代戊酸的結晶形式 |
HK15100168.9A HK1199885A1 (zh) | 2006-12-06 | 2015-01-07 | '- '- '- -叔丁基苯基 草氨酰基 丙氨酰基 氨基- ', ', ', '-四氟苯氧基 -氧代戊酸的結晶形式 |
Country Status (23)
Country | Link |
---|---|
US (1) | US7692038B2 (zh) |
EP (1) | EP2091910B1 (zh) |
JP (1) | JP5495787B2 (zh) |
KR (1) | KR101125932B1 (zh) |
CN (3) | CN103951583B (zh) |
AR (1) | AR064809A1 (zh) |
AU (1) | AU2007330478B2 (zh) |
CA (1) | CA2669849C (zh) |
CL (1) | CL2007003491A1 (zh) |
DK (1) | DK2091910T3 (zh) |
ES (1) | ES2524021T3 (zh) |
HK (3) | HK1138567A1 (zh) |
HN (1) | HN2007000536A (zh) |
IL (1) | IL198732A (zh) |
MX (1) | MX2009006055A (zh) |
NO (1) | NO338908B1 (zh) |
PA (1) | PA8759501A1 (zh) |
PE (1) | PE20081251A1 (zh) |
PL (1) | PL2091910T3 (zh) |
PT (1) | PT2091910E (zh) |
TW (1) | TWI345466B (zh) |
UY (1) | UY30758A1 (zh) |
WO (1) | WO2008068615A1 (zh) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104876937B (zh) * | 2010-02-12 | 2017-07-28 | 辉瑞公司 | 8‑氟‑2‑{4‑[(甲氨基)甲基]苯基}‑1,3,4,5‑四氢‑6H‑氮杂*并[5,4,3‑cd]吲哚‑6‑酮的马来酸盐、其药物组合物及其用途 |
CN103113405B (zh) * | 2012-10-17 | 2016-03-02 | 上海日馨生物科技有限公司 | 苯磷硫胺多晶型体、制备方法及其应用 |
KR20240010105A (ko) * | 2014-03-14 | 2024-01-23 | 아지오스 파마슈티컬스 아이엔씨. | 치료적으로 활성인 화합물의 약제학적 조성물 |
MX2016014731A (es) | 2014-05-12 | 2017-05-04 | Conatus Pharmaceuticals Inc | Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa. |
SG11201700958YA (en) * | 2014-09-08 | 2017-03-30 | Pfizer | Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole |
NZ734041A (en) | 2015-01-30 | 2022-02-25 | Vertex Pharma | Crystalline forms of c21h22cl2n4o2 |
WO2016144830A1 (en) | 2015-03-06 | 2016-09-15 | Concert Pharmaceuticals, Inc. | Deuterated emricasan |
CN105017061B (zh) * | 2015-07-07 | 2017-03-29 | 苏州富士莱医药股份有限公司 | 一种恩利卡生的合成方法 |
WO2017079566A1 (en) | 2015-11-05 | 2017-05-11 | Conatus Pharmaceuticals, Inc. | Caspase inhibitors for use in the treatment of liver cancer |
US20190022043A1 (en) | 2015-12-31 | 2019-01-24 | Conatus Pharmaceuticals Inc. | Methods of using caspase inhibitors in treatment of liver disease |
JP2019530696A (ja) | 2016-10-05 | 2019-10-24 | ノバルティス アーゲー | 線維性、硬変性の疾患もしくは障害を治療または予防するためのfxrアゴニストを含む組合せ組成物 |
TWI764977B (zh) * | 2017-01-23 | 2022-05-21 | 大陸商正大天晴藥業集團股份有限公司 | 作爲caspase抑制劑的聯環化合物、含有其的藥物組合物及其應用 |
WO2018172950A1 (en) * | 2017-03-23 | 2018-09-27 | Novartis Ag | Anhydrous crystalline forms of sodium (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinolinecarboxylate |
CA3058280C (en) * | 2017-03-30 | 2023-11-28 | Merck Patent Gmbh | Crystalline form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol |
AR114251A1 (es) * | 2018-02-13 | 2020-08-12 | Syngenta Participations Ag | Formas cristalinas de n-[2-(2,4-diclorofenil)ciclobutil]-2-(trifluorometl)piridin-3-carboxamida |
WO2020006341A1 (en) | 2018-06-29 | 2020-01-02 | Conatus Pharmaceuticals, Inc. | (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases |
AU2020231396A1 (en) | 2019-03-07 | 2021-10-21 | Nobo Medicine Inc. | Caspase inhibitors and methods of use thereof |
CN111351780A (zh) * | 2019-12-29 | 2020-06-30 | 中船重工(邯郸)派瑞特种气体有限公司 | 一种三氟甲基磺酰氟电解槽中电解液成分的分析方法 |
WO2022123062A1 (en) | 2020-12-11 | 2022-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients |
KR102670554B1 (ko) | 2022-01-04 | 2024-05-30 | 주식회사 이노보테라퓨틱스 | 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE149483T1 (de) * | 1991-07-30 | 1997-03-15 | Ajinomoto Kk | Kristalle von n-(trans-4- isopropylcyclohexylcarbonyl)-d-phenylalanin und verfahren zu ihrer herstellung |
DK0625504T3 (da) * | 1993-05-12 | 1997-12-08 | Heumann Pharma Gmbh & Co | Stabil og krystallinsk form af Bezafibrat |
US6197750B1 (en) * | 1998-07-02 | 2001-03-06 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
US6544951B2 (en) * | 1998-07-02 | 2003-04-08 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
US7053056B2 (en) * | 1998-07-02 | 2006-05-30 | Idun Pharmaceuticals, Inc. | C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
GB9923933D0 (en) * | 1999-10-08 | 1999-12-08 | Smithkline Beecham Lab | Novel pharmaceutical |
ES2302857T3 (es) * | 2001-12-11 | 2008-08-01 | Kyorin Pharmaceutical Co., Ltd. | Cristales estables de derivado del acido fenilpropionico sustituido y procedimiento para su produccion. |
RU2008101383A (ru) * | 2005-07-11 | 2009-07-20 | Пфайзер Лимитед (GB) | НОВАЯ КОМБИНАЦИЯ АНТИMAdCAM-АНТИТЕЛА И ПРОТИВОФИБРОЗНОГО ИНГИБИТОРА КАСПАЗЫ ДЛЯ ЛЕЧЕНИЯ ФИБРОЗА ПЕЧЕНИ |
-
2007
- 2007-12-03 CN CN201410058519.5A patent/CN103951583B/zh active Active
- 2007-12-03 PT PT78590338T patent/PT2091910E/pt unknown
- 2007-12-03 CN CN201410057544.1A patent/CN103923169B/zh not_active Expired - Fee Related
- 2007-12-03 EP EP07859033.8A patent/EP2091910B1/en active Active
- 2007-12-03 CN CN200780045311.8A patent/CN101573328B/zh active Active
- 2007-12-03 AU AU2007330478A patent/AU2007330478B2/en not_active Ceased
- 2007-12-03 DK DK07859033.8T patent/DK2091910T3/en active
- 2007-12-03 KR KR1020097011692A patent/KR101125932B1/ko active IP Right Grant
- 2007-12-03 CA CA2669849A patent/CA2669849C/en active Active
- 2007-12-03 PL PL07859033T patent/PL2091910T3/pl unknown
- 2007-12-03 ES ES07859033.8T patent/ES2524021T3/es active Active
- 2007-12-03 MX MX2009006055A patent/MX2009006055A/es active IP Right Grant
- 2007-12-03 WO PCT/IB2007/003900 patent/WO2008068615A1/en active Application Filing
- 2007-12-03 JP JP2009539823A patent/JP5495787B2/ja active Active
- 2007-12-04 CL CL200703491A patent/CL2007003491A1/es unknown
- 2007-12-04 PA PA20078759501A patent/PA8759501A1/es unknown
- 2007-12-04 UY UY30758A patent/UY30758A1/es not_active Application Discontinuation
- 2007-12-04 HN HN2007000536A patent/HN2007000536A/es unknown
- 2007-12-05 AR ARP070105447A patent/AR064809A1/es not_active Application Discontinuation
- 2007-12-05 PE PE2007001720A patent/PE20081251A1/es not_active Application Discontinuation
- 2007-12-05 TW TW096146304A patent/TWI345466B/zh active
- 2007-12-06 US US11/951,801 patent/US7692038B2/en active Active
-
2009
- 2009-05-13 IL IL198732A patent/IL198732A/en active IP Right Grant
- 2009-05-14 NO NO20091892A patent/NO338908B1/no not_active IP Right Cessation
-
2010
- 2010-05-03 HK HK10104322.9A patent/HK1138567A1/zh not_active IP Right Cessation
-
2015
- 2015-01-07 HK HK15100168.9A patent/HK1199885A1/zh not_active IP Right Cessation
- 2015-01-23 HK HK15100810.1A patent/HK1200440A1/zh not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1200440A1 (zh) | 種抑制劑的結晶形式 | |
ZA200802585B (en) | Pyridopyrimidinone inhibitors of Pl3Kα | |
IL190292A0 (en) | PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka | |
ZA200706345B (en) | Amino-pyridines as inhibitors of ß-secretase | |
IL195031A0 (en) | Uses of dpp-iv inhibitors | |
PL2402317T3 (pl) | Inhibitor DGAT | |
PL2361922T3 (pl) | Produkty pośrednie do wytwarzania inhibitorów nukleozydowych HCV | |
GB0622084D0 (en) | Inhibitors of HSP90 | |
HRP20130144T1 (en) | Renin inhibitors | |
ZA200903971B (en) | Crystalline modification of fipronil | |
IL196000A0 (en) | 2-arylindole derivatives as npges-i inhibitors | |
IL198264A0 (en) | Crystalline modification of fipronil | |
ZA200903970B (en) | Crystalline modification of fipronil | |
EP2162436A4 (en) | NEW CASE OF RENININHIBITORS | |
ZA200903614B (en) | New crystalline forms | |
ZA200903972B (en) | Crystalline modification of fipronil | |
GB0621205D0 (en) | Inhibitors of PLK | |
IL195061A0 (en) | Crystalline forms of atorvastatin | |
IL193025A0 (en) | Crystalline forms of ciclesonide | |
IL206021A0 (en) | Crystalline form of azelastine | |
IL195092A0 (en) | Crystalline form of (s)-1-phenylethylammonium (r)-diphenyl-methanesulphinyl-acetate | |
EP2017254A4 (en) | CRYSTALLIZATION PROCESS | |
AP2717A (en) | Mono-hydrochloric salts of an inhibitor of histonedeacetylase | |
GB0608822D0 (en) | Inhibitors of DHFR | |
GB0622085D0 (en) | Inhibitors of HSP90 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20191201 |